ARS Pharmaceuticals (SPRY) Total Debt (2020 - 2026)

ARS Pharmaceuticals (SPRY) posted Total Debt of $96.5 million for Q1 2026, little changed sequentially from $96.4 million in Q4 2025.

Analysis

ARS Pharmaceuticals (SPRY) Total Debt (2020 - 2026) Analysis & Trends

ARS Pharmaceuticals has reported Total Debt for 4 years, with the latest figure at $96.5 million in Q1 2026.

Quarterly Total Debt changed N/A year-over-year to $96.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.5 million (changed N/A YoY) and the FY2025 annual result came in at $96.4 million, changed N/A from the prior year.
Total Debt held at $96.5 million in Q1 2026 per SPRY's latest filing, from $96.4 million in the prior quarter.
Over five years, Total Debt peaked at $96.5 million in Q1 2026 and troughed at $96.2 million in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	591.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	1.07 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	9.34 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	546.77 Mn
10	ARS Pharmaceuticals	561.12 Mn	417.27 Mn	20.81 Mn	96.68 Mn

Historic Data

Download Data